Momtaz, TanishaAfrin, Sadia2024-10-272024-10-27202220222022-02ID 16346051http://hdl.handle.net/10361/24408Catalogued from PDF version of thesis.Includes bibliographical references (pages 26-31).This thesis is submitted in partial fulfilment of the requirements for the degree of Bachelor of Pharmacy, 2022.Traditional treatments and symptomatic care are still the only options for most patients as no therapeutic drug has been licensed for treating COVID-19 yet. Monoclonal antibodies generated from convalescent patients or humanized mice exposed to SARS-CoV-2 antigens were awarded emergency use authorization. An ongoing phase I, II, and III placebo-controlled trial is testing whether symptomatic adults can be treated safely and effectively. Casirivimab and imdevimab may have a therapeutic benefit in people who were seronegative when they received treatment. An IgG1 (Immunoglobulin G1) with an unaltered Fc region, Bamlanivimab was generated from the convalescent plasma of a COVID-19 patient. Patients with renal impairment, pregnancy, or breastfeeding status are not advised to alter their dosages. SARS-genomic CoV-2's organization is nearly identical to that of SARS-CoV, with the exception of a few genes for accessory proteins.31 pagesenBRAC University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.CasirivimabImdevimabBamlanivimabSARS-CoV-2Immunoglobulin G1Placebo-controlled trialCovid 19--Treatment.Thesis